We do not diagnose disease or recommend a dietary supplement for the treatment of disease. You should share this information with your physician who can determine what nutrition, disease and injury treatment regimen is best for you. You can search this site or the web for topics of interest that I may have written (use Dr Simone and topic).
“We provide truthful information without emotion or influence from the medical establishment, pharmaceutical industry, national organizations, special interest groups or government agencies.” Charles B Simone, M.MS., M.D.
LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES
Lawrenceville, NJ (Dr Simone) – I have written that the LDL cholesterol contributed only modestly to overall risk prediction (Lancet 2014) because people who had the most reduction in inflammation, not LDL, had the least recurrent vascular events (http://www.simonesuperenergy.com/do-you-know-your-ldl-hdl-triglycerides-are-they-important/). And that’s why US guidelines issued by a committee of a mere 15 people no longer advocate treatment to specific LDL targets, but instead suggest using high dose statin for high risk patients.
However, Big Pharma developed antibodies to decrease LDL to very low levels to determine if that made a difference. Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017 (N Engl J Med 2017; 376:1713-1722May 4, 2017DOI: 10.1056/NEJMoa1615664).
Does this scenario look familiar? SUGAR INDUSTRY SECRETLY PAID FOR FAVORABLE HARVARD RESEARCH (http://www.simonesuperenergy.com/sugar-industry-secretly-paid-for-favorable-harvard-research/)
Salient points of this LDL study:
1) 27,564 patients – the larger the number, the easier it is for statisticians to bias the findings.
2) Primary end point was 9.8% for the treatment group and 11.3% for the control group. These numbers don’t look very different. This included: cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization (Hazard Ratio = 0.85).
3) More deaths in the treatment group (cardiovascular deaths and deaths from any cause – Table 2).
4) The authors failed to mention that ‘serious adverse events’ cover all serious cardiovascular and non-cardiovascular disease. They double-counted the cardiovascular events, first as part of the primary outcome and later among the ‘serious adverse events’. As a result, it is suggested that the risk of unintended serious events is equal in both groups. In reality, the increased risk of serious adverse non-cardiovascular events is negated by the reduced risk of serious adverse cardiovascular events.
5) Cost = $14,300 per patient per year
Hazard Ratio Defined:
If the Hazard Ratio = 2, then the treatment causes twice as much harm.
If the Hazard Ratio = 10, then the treatment causes ten times as much harm.
If the Hazard Ratio = 1, there is no benefit from the treatment.
If the Hazard Ratio = 1.2, then the treatment causes 20% more harm.
If the Hazard Ratio = 0.80, then there is a 20% benefit from the treatment.
BOTTOM LINE: If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. Wall Street wasn’t impressed, but some physicians will prescribe lots of it.
IT’S ALL ABOUT INFLAMMATION AND OXIDATION. Lipids are markers of foods that increase inflammation and oxidation. So if you take prescription medications or herbals to lower your lipids but continue eating high fat, high sugar, low fiber foods, you will continue to cause inflammation and oxidation in your body. Other controllable risk factors like smoking, alcohol, etc, also increase inflammation and oxidation. (INFLAMMATION AND OXIDATION – WHAT YOU CAN DO http://www.simonesuperenergy.com/inflammation-and-oxidation-what-you-can-do/ ). You should consider taking antioxidants in the correct doses, correct chemical forms, and correct ratios of one to another. Also take anti-inflammatory agents.